Bioxytran Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	2020 - 2017
Period Ending	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	2020 - 2017
Net Income	-2.12	-2.37	-4.47	-2.46	-4.03	Upgrade
Depreciation & Amortization	0.01	0.01	0.01	0	-	Upgrade
Other Amortization	-	0.68	0.35	0.31	0.08	Upgrade
Stock-Based Compensation	0.38	0.44	0.18	0.18	0.58	Upgrade
Other Operating Activities	0.22	-0.25	-0.04	-0.14	-0.5	Upgrade
Change in Accounts Payable	1.13	1.11	2.22	0.3	1.9	Upgrade
Change in Other Net Operating Assets	-0.14	-	0.99	-	0.27	Upgrade
Operating Cash Flow	-0.53	-0.38	-0.78	-1.81	-1.7	Upgrade
Sale (Purchase) of Intangibles	-0.02	-0.03	-0.04	-0.03	-0.04	Upgrade
Investing Cash Flow	-0.02	-0.03	-0.04	-0.03	-0.04	Upgrade
Short-Term Debt Issued	0.32	0.33	-	1.38	1.17	Upgrade
Total Debt Issued	0.32	0.33	-	1.38	1.17	Upgrade
Net Debt Issued (Repaid)	0.32	0.33	-	1.38	1.17	Upgrade
Issuance of Common Stock	0.44	0.06	0.55	0.68	-	Upgrade
Other Financing Activities	0.29	-	-	-	0.6	Upgrade
Financing Cash Flow	1.05	0.39	0.55	2.06	1.77	Upgrade
Net Cash Flow	0.5	-0.02	-0.27	0.22	0.03	Upgrade
Cash Interest Paid	-	0.16	0.05	0.1	-	Upgrade
Levered Free Cash Flow	0.25	-1.26	-2.54	-0.86	-1.43	Upgrade
Unlevered Free Cash Flow	0.37	-1.46	-2.42	-0.84	-1.31	Upgrade
Change in Working Capital	0.99	1.11	3.2	0.3	2.17	Upgrade

Source: S&P Capital IQ. Standard template. Financial Sources.